Serum levels of GDF15 have been reported to be increased in MS patients24 and were also higher in patients with CIS/MS (n = 30) in our study although the difference from healthy controls (n = 10) was not statistically different (p = 0.057) (Fig. 7a). Here, GDF15 is linked to myeloid sarcoma.